drugset
Drugs / TTC-352
last change Feb 2023 re-read 3 minutes ago

TTC-352

also known as SHERPA TTC-352

Small molecule

Developed for
estrogen-receptor positive breast cancer
Investigated by
TTC Oncology, LLC

Trials 1

today NCT03201913 · Ph 1
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03201913 Dec 2017 → Dec 2019 estrogen-receptor positive breast cancer TTC Oncology, LLC Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2023-02-27 Lantern Pharma Inc. Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352 lanternpharma.com ↗

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as TTC-352 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03201913 ↗
Known as SHERPA TTC-352 ChEMBL registry synonym — accepted as the source's own label CHEMBL3763743 ↗
Action Activate “TTC-352 is a selective human estrogen receptor (ER) partial agonist” PMID 32696319 ↗ Jul 2020
Modality Small molecule — CHEMBL3763743 ↗
Route Oral “TTC-352 administered as an oral capsule” NCT03201913 ↗